Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630 | 0.98 | TDP1 (0.58) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL12002403 | 0.98 | TDP1 (0.58) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL13811429 | 0.98 | TDP1 (0.58) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL15246779 | 0.98 | TDP1 (0.58) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL21630227 | 0.94 | TDP1 (0.53) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL21630218 | 0.94 | TDP1 (0.53) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL742860 | 0.91 | TDP1 (0.50) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL21630232 | 0.91 | TDP1 (0.50) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| Ether SCHEMBL936894 | 0.90 | ALDH1A1 (0.50) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL22476674 | 0.88 | TDP1 (0.50) | TDP1ALDH1A1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180264165-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2018-09-20 | — | — | US | claimed |
| US-9358319-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-20140357754-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2014-12-04 | — | — | US | claimed |
| EP-2192886-A2 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | Pioneer Surgical Technology, Inc. (US) | 2010-06-09 | — | — | EP | claimed |
| US-20090270527-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | ANGSTROM MEDICA (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009029734-A2 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2009-03-05 | — | — | WO | claimed |
| US-10799610-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10413632-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180264165-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2018-09-20 | — | — | US | disclosed |
| US-9993576-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2192886-B1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | PIONEER SURGICAL TECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170333594-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2017-11-23 | — | — | US | disclosed |
| US-9757493-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-8815973-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110004307-A1 | FUSION DEVICE, SYSTEMS AND METHODS THEREOF | TUTOGEN MEDICAL, INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2192886-A2 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | Pioneer Surgical Technology, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270527-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | ANGSTROM MEDICA (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2083760-A2 | FUSION DEVICE, SYSTEMS AND METHODS THEREOF | Pioneer Surgical Technology, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009029734-A2 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008140551-A2 | FUSION DEVICE | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180264165-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | BHMT2, SHMT1, BHMT | MEN1 1120/4885TDP1 4090/4885ALDH1A1 844/4885 |
| US-20170333594-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | BHMT2, SHMT1, BHMT | MEN1 1120/4885TDP1 4090/4885ALDH1A1 844/4885 |
| US-10799610-B2 | Cement products and methods of making and using the same | BHMT2, SHMT1, BHMT | MEN1 1120/4885TDP1 4090/4885ALDH1A1 844/4885 |
| US-10413632-B2 | Cement products and methods of making and using the same | BHMT2, SHMT1, BHMT | MEN1 1120/4885TDP1 4090/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.